(AKZA) Akzo Nobel - Ratings and Ratios
Paints, Coatings, Varnishes, Lacquers, Specialty Chemicals
AKZA EPS (Earnings per Share)
AKZA Revenue
Description: AKZA Akzo Nobel
Akzo Nobel NV is a global paints and coatings company operating in two main segments: Decorative Paints and Performance Coatings. The company offers a wide range of products, including paints, lacquers, varnishes, and powder coatings, under various brands such as Dulux, Sikkens, and International. Akzo Nobel serves various industries, including energy, packaging, infrastructure, and shipbuilding, as well as general industries like agricultural and construction equipment.
From a financial perspective, Akzo Nobel has a market capitalization of approximately €10.1 billion, indicating a significant presence in the specialty chemicals sector. The companys return on equity (RoE) stands at 10.26%, suggesting a decent level of profitability. To further analyze the companys performance, key performance indicators (KPIs) such as revenue growth, EBITDA margin, and debt-to-equity ratio can be examined. For instance, a stable EBITDA margin would indicate the companys ability to maintain profitability, while a manageable debt-to-equity ratio would suggest a healthy capital structure.
To gain a deeper understanding of Akzo Nobels competitive position, its essential to analyze its market share, brand portfolio, and product offerings. The companys diverse brand portfolio and wide range of products enable it to cater to various customer needs. Additionally, Akzo Nobels presence in multiple industries and geographies provides a degree of diversification, potentially reducing its dependence on any single market. Key metrics such as sales growth, market share, and customer satisfaction can help assess the companys competitive strength.
From an investment perspective, Akzo Nobels stock has a forward price-to-earnings (P/E) ratio of 14.47, which can be compared to industry averages to determine if the stock is undervalued or overvalued. Other relevant metrics, such as dividend yield and payout ratio, can also be examined to assess the stocks attractiveness. For example, a stable dividend yield and a reasonable payout ratio may indicate a attractive investment opportunity.
AKZA Stock Overview
| Market Cap in USD | 12,275m |
| Sub-Industry | Specialty Chemicals |
| IPO / Inception |
AKZA Stock Ratings
| Growth Rating | -5.0% |
| Fundamental | 51.6% |
| Dividend Rating | 44.0% |
| Return 12m vs S&P 500 | -6.67% |
| Analyst Rating | - |
AKZA Dividends
| Dividend Yield 12m | 3.33% |
| Yield on Cost 5y | 2.63% |
| Annual Growth 5y | 0.62% |
| Payout Consistency | 89.2% |
| Payout Ratio | 62.3% |
AKZA Growth Ratios
| Growth Correlation 3m | 3.4% |
| Growth Correlation 12m | 17.9% |
| Growth Correlation 5y | -78.3% |
| CAGR 5y | 4.37% |
| CAGR/Max DD 3y | 0.13 |
| CAGR/Mean DD 3y | 0.28 |
| Sharpe Ratio 12m | -0.15 |
| Alpha | -11.11 |
| Beta | 0.856 |
| Volatility | 23.19% |
| Current Volume | 329.3k |
| Average Volume 20d | 305.1k |
| Stop Loss | 59.3 (-3.1%) |
| Signal | 0.53 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (415.0m TTM) > 0 and > 6% of Revenue (6% = 631.6m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA -1.27pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 11.10% (prev 5.16%; Δ 5.93pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 814.0m > Net Income 415.0m (YES >=105%, WARN >=100%) |
| Net Debt (3.77b) to EBITDA (792.0m) ratio: 4.77 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.23 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (171.0m) change vs 12m ago 0.12% (target <= -2.0% for YES) |
| Gross Margin 39.85% (prev 40.90%; Δ -1.05pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 73.47% (prev 73.83%; Δ -0.36pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.42 (EBITDA TTM 792.0m / Interest Expense TTM 179.0m) >= 6 (WARN >= 3) |
Altman Z'' 2.05
| (A) 0.08 = (Total Current Assets 6.33b - Total Current Liabilities 5.16b) / Total Assets 14.17b |
| (B) 0.35 = Retained Earnings (Balance) 4.95b / Total Assets 14.17b |
| (C) 0.06 = EBIT TTM 792.0m / Avg Total Assets 14.33b |
| (D) 0.0 = Book Value of Equity 0.0 / Total Liabilities 9.79b |
| Total Rating: 2.05 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 51.63
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield 2.57% = 1.28 |
| 3. FCF Margin 4.56% = 1.14 |
| 4. Debt/Equity 2.35 = 0.24 |
| 5. Debt/Ebitda 12.35 = -2.50 |
| 6. ROIC - WACC 2.67% = 3.34 |
| 7. RoE 9.25% = 0.77 |
| 8. Rev. Trend -39.59% = -1.98 |
| 9. Rev. CAGR -3.08% = -0.51 |
| 10. EPS Trend 49.12% = 1.23 |
| 11. EPS CAGR 16.23% = 1.62 |
What is the price of AKZA shares?
Over the past week, the price has changed by -1.03%, over one month by +9.25%, over three months by +4.79% and over the past year by +10.37%.
Is Akzo Nobel a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of AKZA is around 57.19 EUR . This means that AKZA is currently overvalued and has a potential downside of -6.55%.
Is AKZA a buy, sell or hold?
What are the forecasts/targets for the AKZA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 68.9 | 12.6% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 61.7 | 0.8% |
AKZA Fundamental Data Overview
Market Cap EUR = 10.47b (10.47b EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 1.55b EUR (Cash only, last quarter)
P/E Trailing = 25.3942
P/E Forward = 13.5685
P/S = 0.9945
P/B = 2.509
P/EG = 1.0419
Beta = 1.011
Revenue TTM = 10.53b EUR
EBIT TTM = 792.0m EUR
EBITDA TTM = 792.0m EUR
Long Term Debt = 4.62b EUR (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 5.16b EUR (from totalCurrentLiabilities, last quarter)
Debt = 9.79b EUR (Calculated: Short Term 5.16b + Long Term 4.62b)
Net Debt = 3.77b EUR (from netDebt column, last fiscal year)
Enterprise Value = 18.70b EUR (10.47b + Debt 9.79b - CCE 1.55b)
Interest Coverage Ratio = 4.42 (Ebit TTM 792.0m / Interest Expense TTM 179.0m)
FCF Yield = 2.57% (FCF TTM 480.0m / Enterprise Value 18.70b)
FCF Margin = 4.56% (FCF TTM 480.0m / Revenue TTM 10.53b)
Net Margin = 3.94% (Net Income TTM 415.0m / Revenue TTM 10.53b)
Gross Margin = 39.85% ((Revenue TTM 10.53b - Cost of Revenue TTM 6.33b) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 18.70b / Book Value Of Equity 0.0)
Interest Expense / Debt = 0.69% (Interest Expense 68.0m / Debt 9.79b)
Taxrate = 29.36% (246.0m / 838.0m)
NOPAT = 559.5m (EBIT 792.0m * (1 - 29.36%))
Current Ratio = 1.23 (Total Current Assets 6.33b / Total Current Liabilities 5.16b)
Debt / Equity = 2.35 (Debt 9.79b / last Quarter total Stockholder Equity 4.17b)
Debt / EBITDA = 12.35 (Net Debt 3.77b / EBITDA 792.0m)
Debt / FCF = 20.39 (Debt 9.79b / FCF TTM 480.0m)
Total Stockholder Equity = 4.49b (last 4 quarters mean)
RoA = 2.93% (Net Income 415.0m, Total Assets 14.17b )
RoE = 9.25% (Net Income TTM 415.0m / Total Stockholder Equity 4.49b)
RoCE = 8.70% (Ebit 792.0m / (Equity 4.49b + L.T.Debt 4.62b))
RoIC = 7.65% (NOPAT 559.5m / Invested Capital 7.32b)
WACC = 4.98% (E(10.47b)/V(20.25b) * Re(9.17%)) + (D(9.79b)/V(20.25b) * Rd(0.69%) * (1-Tc(0.29)))
Shares Correlation 3-Years: -78.16 | Cagr: -0.87%
Discount Rate = 9.17% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 65.53% ; FCFE base≈557.6m ; Y1≈366.1m ; Y5≈167.4m
Fair Price DCF = 16.08 (DCF Value 2.75b / Shares Outstanding 171.0m; 5y FCF grow -40.0% → 3.0% )
Revenue Correlation: -39.59 | Revenue CAGR: -3.08%
Rev Growth-of-Growth: 0.35
EPS Correlation: 49.12 | EPS CAGR: 16.23%
EPS Growth-of-Growth: -61.64